Lesley Murray

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations

Medicine, Oncology, Pharmacology +15

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen et al. · Blood · 2003 · 857 citations · Full text

Medicine, Oncology, Pharmacology +11

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

Tinya J. Abrams, Leslie B. Lee, Lesley Murray et al. · PubMed · 2003 · 639 citations

Medicine, Oncology, Pharmacology +17

<i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

Klaus P. Hoeflich, Carol O’Brien, Zachary Boyd et al. · Clinical Cancer Research · 2009 · 473 citations

Medicine, Oncology, Pharmacology +17

Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents

Michael Degtyarev, Ann De Mazière, Christine Orr et al. · The Journal of Cell Biology · 2008 · 410 citations · Full text

Life Sciences, Cell Biology, Oncology +17